Trends, Challenges and Opportunities of Epigenetic Therapeutics in Cancer

3:00 PM - 4:00 PM (PDT), Tuesday, June 14, 2022 ・ Upper Level, Session Room 6C

In recent times, the epigenetic drug discovery field has made substantial progress. So far, inhibitors targeting three epigenetic targets have been approved, including the first epigenetic inhibitor for solid tumors, and a plethora of molecules are progressing in clinical trials. Challenges of toxicity are being addressed by creative dosing regimens and combination therapies to ascertain positive outcomes in various cancer indications. Patient stratification for addressing the right population are being approached with innovative biomarker discovery strategies. Substantial literature evidence presents opportunities for epigenetic therapies in diverse malignancies such as neuro endocrine cancer.

President & Chief Executive Officer
Jubilant Therapeutics, Inc.
Scientific Director, Center for Functional Cancer Epigenetics
Dana-Farber Cancer Institute
Senior Director
Pfizer La Jolla Laboratories